Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
BBLG: 188% | Bone Biologics Files USPTO Patent For rhNELL-1 Protein In Bone Regeneration Therapy
INMB: 130% | INmune Bio shares are trading higher after the company revealed top-line results from its MINDFuL Phase 2 trial.